ImmuCell Corp (ICCC) stock
Close on Nov 12, 2026Market cap $92.82MP/E 51.1Yield –
ImmuCell Corp grew revenue 19.6% to $33.21M over the twelve months to Sep 30, 2026. Operating income rose 106.3% to $4.80M, moving the operating margin from 8.4% to 14.5%. Free cash flow was $5.40M, up 655.1% from a year earlier. At the latest close the market valued the company at $92.82M, 51.1 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $92.82M
- P/E ratio
- 51.1
- Price to sales
- 2.79
- Price to book
- 2.83
- Dividend yield
- –
- Free cash flow yield
- 5.82%
Fundamentals
- Revenue
- $33.21M
- Net income
- $1.88M
- EPS, diluted
- $0.20
- Free cash flow
- $5.40M
- Book value per share
- $3.53
- Diluted shares
- 9M
Trading
- Next earnings
- Mar 3, 2027 (estimated, after the close)
- Previous close
- $10.19
- Open
- $10.21
- Day's range
- $10.20 – $10.32
- Volume
- 19,304
- Average volume (20 days)
- 6,047
- Beta (5 years)
- 0.10
- 52-week range
- $4.52 – $12.10
- RSI (14 days)
- 50.1
- Volatility (1 year)
- 50.6%
- Relative volume
- 1.02×
- WACC
- 7.2%
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ICCC | S&P 500 | Difference | ICCC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +6.5% | -2.7% | +9.2 pts | ||
| 3 months | -6.9% | -1.7% | −5.2 pts | ||
| Year to date | +66.2% | +11.9% | +54.3 pts | ||
| 1 year | +66.7% | +12.0% | +54.7 pts | ||
| 3 years | +89.3% | +78.2% | +11.1 pts | +23.7% | +21.2% |
| 5 years | +10.8% | +73.2% | −62.4 pts | +2.1% | +11.6% |
| 10 years | +98.1% | +309.6% | −211.6 pts | +7.1% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases ImmuCell filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- News
About ImmuCell
In Vitro & In Vivo Diagnostic Substances
ImmuCell Corporation is an animal health biologics enterprise that develops, produces, and markets products designed to enhance the health, survivability, and performance of newborn dairy and beef calves. Its core offering is the First Defense product line, which uses hyperimmunized bovine colostrum to deliver pathogen-specific antibodies that protect young calves against scours, a severe diarrheal condition caused by bovine coronavirus, rotavirus, and E. coli. The product portfolio includes single-dose boluses, gel formulations, and bulk powder functional feed ingredients marketed as First Defense Technology. In addition, the business supplies a diagnostic tool known as the California Mastitis Test. ImmuCell serves commercial dairy operations, specialized calf ranches, and beef producers, selling its products through a commercial team in partnership with international, national, and regional animal health distributors.
Company profile, executives and historyImmuCell stock: common questions
What is ImmuCell's stock price?
ICCC closed at $10.22 on Nov 12, 2026, up 0.29% on the day. Over the past 52 weeks it traded between $4.52 and $12.10.
What is ImmuCell's market cap?
ImmuCell was worth $92.82M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ICCC's P/E ratio?
ICCC trades at 51.1 times earnings, based on diluted earnings per share of $0.20 over the twelve months to Sep 30, 2026.
How much revenue does ImmuCell make?
ImmuCell reported revenue of $33.21M for the twelve months to Sep 30, 2026, up 19.6% from a year earlier.
Does ImmuCell pay a dividend?
No. ImmuCell has not paid a cash dividend over the last twelve months.
When does ImmuCell report earnings next?
ImmuCell is expected to report Q4 FY2026 results on Mar 3, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ICCC stock performed over the past year?
Including dividends, ICCC returned +66.7% over the past year, against +12.0% for the S&P 500.
How many ICCC shares are sold short?
0M shares were sold short at the latest FINRA report, 0.19% of the float, or 2.8 days of average trading volume.
Who are ImmuCell's competitors?
Companies most similar to ImmuCell by business, industry and size include TKNO, TRIB, ZOMDF, JAGX, BMRA.
See a number that looks wrong?